Pharmacotherapy of social anxiety disorder

Expert Opinion on Pharmacotherapy

Volumn 12, Issue 4, 2011, Pages 615-625

  Schneier, Franklin R ^a  

^a New York State Psychiatric Institute ^*  (United States)

Author keywords

Anxiety disorders; Benzodiazepine; Monoamine oxidase inhibitors; Serotonin reuptake inhibitors; Social phobia

Indexed keywords

ANTIDEPRESSANT AGENT; ATOMOXETINE; BENZODIAZEPINE DERIVATIVE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BROFAROMINE; BUSPIRONE; CLONAZEPAM; DULOXETINE; ESCITALOPRAM; ETIRACETAM; FLUVOXAMINE; GABAPENTIN; MIRTAZAPINE; MOCLOBEMIDE; MONOAMINE OXIDASE INHIBITOR; OLANZAPINE; PAROXETINE; PHENELZINE; PINDOLOL; PLACEBO; PREGABALIN; QUETIAPINE; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TIAGABINE; TOPIRAMATE; TRANYLCYPROMINE; VALPROIC ACID; VENLAFAXINE;

ALCOHOL CONSUMPTION; ATTENTION DEFICIT DISORDER; CLINICAL FEATURE; COMORBIDITY; CONTROLLED CLINICAL TRIAL (TOPIC); COORDINATION DISORDER; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DIZZINESS; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; EVIDENCE BASED MEDICINE; FALLING; FATIGUE; HUMAN; HYPERHIDROSIS; INSOMNIA; LOW DRUG DOSE; MONOTHERAPY; NAUSEA; PATIENT ASSESSMENT; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SEDATION; SEXUAL DYSFUNCTION; SIDE EFFECT; SOCIAL PHOBIA; SOMNOLENCE; TREATMENT DURATION; WEIGHT GAIN; XEROSTOMIA;

ANIMALS; ANTIDEPRESSIVE AGENTS; BENZODIAZEPINES; COGNITIVE THERAPY; COMBINED MODALITY THERAPY; EVIDENCE-BASED MEDICINE; HUMANS; PHOBIC DISORDERS;

EID: 79951615933     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.2011.534983     Document Type: Review

References (80)

1. Kessler RC, Berglund P, Demler O, et al. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005;62(6):593-602 (Pubitemid 40973434)
2. Grant BF, Hasin DS, Blanco C, et al. The epidemiology of social anxiety disorder in the United States: results from the National Epidemiologic Survey on alcohol and related conditions. J Clin Psychiatry 2005;66(11):1351-61 (Pubitemid 41779531)
3. Katzelnick DJ, Kobak KA, DeLeire T, et al. Impact of generalized social anxiety disorder in managed care. Am J Psychiatry 2001;158(12):1999-2007 (Pubitemid 33104105)
4. Cougle JR, Keough ME, Riccardi CJ, Sachs-Ericsson N. Anxiety disorders and suicidality in the National Comorbidity Survey-Replication. J Psychiatr Res 2009;43(9):825-9
5. Olfson M, Guardino M, Struening E, et al. Barriers to the treatment of social anxiety. Am J Psychiatry 2000;157(4):521-7 (Pubitemid 30191190)
6. Connor KM, Davidson JR, Chung H, et al. Multidimensional effects of sertraline in social anxiety disorder. Depress Anxiety 2006;23(1):6-10
7. Schultz LT, Heimberg RG. Attentional focus in social anxiety disorder: potential for interactive processes. Clin Psychol Rev 2008;28(7):1206-21
8. Kessler RC, Stein MB, Berglund P. Social phobia subtypes in the National Comorbidity Survey. Am J Psychiatry 1998;155(5):613-19 (Pubitemid 28225400)
9. Kendler KS, Neale MC, Kessler RC, et al. The genetic epidemiology of phobias in women. The interrelationship of agoraphobia, social phobia, situational phobia, and simple phobia. Arch Gen Psychiatry 1992;49(4):273-81
10. Rapee RM, Spence SH. The etiology of social phobia: empirical evidence and an initial model. Clin Psychol Rev 2004;24(7):737-67 (Pubitemid 39388871)
11. Stein MB, Goldin PR, Sareen J, et al. Increased amygdala activation to angry and contemptuous faces in generalized social phobia. Arch Gen Psychiatry 2002;59(11):1027-34
12. Lissek S, Levenson J, Biggs AL, et al. Elevated fear conditioning to socially relevant unconditioned stimuli in social anxiety disorder. Am J Psychiatry 2008;165(1):124-32 (Pubitemid 351704561)
13. Argyropoulos SV, Hood SD, Nutt DJ. Social phobia: illness or illusion? Acta Psychiatr Scand 2001;103(4):241-3
14. Cornwell BR, Johnson L, Berardi L, Grillon C. Anticipation of public speaking in virtual reality reveals a relationship between trait social anxiety and startle reactivity. Biol Psychiatry 2006;59(7):664-6 (Pubitemid 43357962)
15. Hoge EA, Pollack MH, Kaufman RE, et al. Oxytocin levels in social anxiety disorder. CNS Neurosci Ther 2008;14(3):165-70
16. Liebowitz MR, Gorman JM, Fyer AJ, Klein DF. Social phobia. Review of a neglected anxiety disorder. Arch Gen Psychiatry 1985;42(7):729-36 (Pubitemid 15054619)
17. Liebowitz MR. Social phobia. Mod Probl Pharmacopsychiatry 1987;22:141-73
18. Zaider TI, Heimberg RG, Fresco DM, et al. Evaluation of the clinical global impression scale among individuals with social anxiety disorder. Psychol Med 2003;33(4):611-22 (Pubitemid 36626043)
19. Oosterbaan DB, van Balkom AJ, Spinhoven P, van Dyck R. The placebo response in social phobia. J Psychopharmacol 2001;15(3):199-203 (Pubitemid 32808255)
20. Ipser JC, Kariuki CM, Stein DJ. Pharmacotherapy for social anxiety disorder: a systematic review. Expert Rev Neurother 2008;8(2):235-57 (Pubitemid 351281112)
21. Hedges DW, Brown BL, Shwalb DA, et al. The efficacy of selective serotonin reuptake inhibitors in adult social anxiety disorder: a meta-analysis of double-blind, placebo-controlled trials. J Psychopharmacol 2007;21(1):102-11 (Pubitemid 46012089)
22. Kobak KA, Greist JH, Jefferson JW, Katzelnick DJ. Fluoxetine in social phobia: a double-blind, placebo-controlled pilot study. J Clin Psychopharmacol 2002;22(3):257-62 (Pubitemid 34546840)
23. Clark DM, Ehlers A, McManus F, et al. Cognitive therapy versus fluoxetine in generalized social phobia: a randomized placebo-controlled trial. J Consult Clin Psychol 2003;71(6):1058-67 (Pubitemid 37448896)
24. Stein MB, Pollack MH, Bystritsky A, et al. Efficacy of low and higher dose extended-release venlafaxine in generalized social anxiety disorder: a 6-month randomized controlled trial. Psychopharmacology (Berl) 2005;177(3):280-8 (Pubitemid 40137288)
25. Lader M, Stender K, Burger V, Nil R. Efficacy and tolerability of escitalopram in 12- and 24-week treatment of social anxiety disorder: randomised, double-blind, placebo-controlled, fixed-dose study. Depress Anxiety 2004;19(4):241-8 (Pubitemid 39014144)
26. Liebowitz MR, Stein MB, Tancer M, et al. A randomized, double-blind, fixed-dose comparison of paroxetine and placebo in the treatment of generalized social anxiety disorder. J Clin Psychiatry 2002;63(1):66-74 (Pubitemid 34113490)
27. Simon NM, Worthington JJ, Moshier SJ, et al. Duloxetine for the treatment of generalized social anxiety disorder: a preliminary randomized trial of increased dose to optimize response. CNS Spectr 2010;15(7):367-73
28. Pallanti S, Quercioli L. Resistant social anxiety disorder response to Escitalopram. Clin Pract Epidemiol Ment Health 2006;2:35
29. Altamura AC, Pioli R, Vitto M, Mannu P. Venlafaxine in social phobia: a study in selective serotonin reuptake inhibitor non-responders. Int Clin Psychopharmacol 1999;14(4):239-45 (Pubitemid 29358991)
30. Baldwin DS, Stein DJ, Dolberg OT, Bandelow B. How long should a trial of escitalopram treatment be in patients with major depressive disorder, generalised anxiety disorder or social anxiety disorder? An exploration of the randomised controlled trial database. Hum psychopharmacol 2009;24(4):269-75
31. Stein DJ, Stein MB, Pitts CD, et al. Predictors of response to pharmacotherapy in social anxiety disorder: an analysis of 3 placebo-controlled paroxetine trials. J Clin Psychiatry 2002;63(2):152-5 (Pubitemid 34173853)
32. Montgomery SA, Nil R, Durr-Pal N, et al. A 24-week randomized, double-blind, placebo-controlled study of escitalopram for the prevention of generalized social anxiety disorder. J Clin Psychiatry 2005;66(10):1270-8 (Pubitemid 41546506)
33. Stein DJ, Versiani M, Hair T, Kumar R. Efficacy of paroxetine for relapse prevention in social anxiety disorder: a 24-week study. Arch Gen Psychiatry 2002;59(12):1111-18 (Pubitemid 35424021)
34. Walker JR, Van Ameringen MA, Swinson R, et al. Prevention of relapse in generalized social phobia: results of a 24-week study in responders to 20 weeks of sertraline treatment. J Clin Psychopharmacol 2000;20(6):636-44
35. Liebowitz MR, Schneier F, Campeas R, et al. Phenelzine vs atenolol in social phobia. A placebo-controlled comparison. Arch Gen Psychiatry 1992;49(4):290-300
36. Nardi AE, Lopes FL, Valenca AM, et al. Double-blind comparison of 30 and 60 mg tranylcypromine daily in patients with panic disorder comorbid with social anxiety disorder. Psychiatry Res 2010;175(3):260-5
37. Versiani M, Nardi AE, Mundim FD, et al. The long-term treatment of social phobia with moclobemide. Int Clin Psychopharmacol 1996;11(Suppl 3):83-8 (Pubitemid 26373760)
38. Muehlbacher M, Nickel MK, Nickel C, et al. Mirtazapine treatment of social phobia in women: a randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol 2005;25(6):580-3 (Pubitemid 41669054)
39. Van Ameringen M, Mancini C, Oakman J, et al. Nefazodone in the treatment of generalized social phobia: a randomized, placebo-controlled trial. J Clin Psychiatry 2007;68(2):288-95 (Pubitemid 46362651)
40. Emmanuel NP, Brawman-Mintzer O, Morton WA, et al. Bupropion-SR in treatment of social phobia. Depress Anxiety 2000;12(2):111-13
41. Simpson HB, Schneier FR, Campeas RB, et al. Imipramine in the treatment of social phobia. J Clin Psychopharmacol 1998;18(2):132-5 (Pubitemid 28192973)
42. Vasile RG, Bruce SE, Goisman RM, et al. Results of a naturalistic longitudinal study of benzodiazepine and SSRI use in the treatment of generalized anxiety disorder and social phobia. Depress Anxiety 2005;22(2):59-67 (Pubitemid 41598041)
43. Davidson JR, Potts N, Richichi E, et al. Treatment of social phobia with clonazepam and placebo. J Clin Psychopharmacol 1993;13(6):423-8 (Pubitemid 24026104)
44. Otto MW, Pollack MH, Gould RA, et al. A comparison of the efficacy of clonazepam and cognitive-behavioral group therapy for the treatment of social phobia. J Anxiety Disord 2000;14(4):345-58 (Pubitemid 30665663)
45. Gelernter CS, Uhde TW, Cimbolic P, et al. Cognitive-behavioral and pharmacological treatments of social phobia. A controlled study. Arch Gen Psychiatry 1991;48(10):938-45
46. Connor KM, Davidson JR, Potts NL, et al. Discontinuation of clonazepam in the treatment of social phobia. J Clin Psychopharmacol 1998;18(5):373-8 (Pubitemid 28462626)
47. Seedat S, Stein MB. Double-blind, placebo-controlled assessment of combined clonazepam with paroxetine compared with paroxetine monotherapy for generalized social anxiety disorder. J Clin Psychiatry 2004;65(2):244-8
48. Turner SM, Beidel DC, Jacob RG. Social phobia: a comparison of behavior therapy and atenolol. J Consult Clin Psychol 1994;62(2):350-8 (Pubitemid 24129514)
49. Stein MB, Sareen J, Hami S, Chao J. Pindolol potentiation of paroxetine for generalized social phobia: a double-blind, placebo-controlled, crossover study. Am J Psychiatry 2001;158(10):1725-7 (Pubitemid 32923671)
50. Pande AC, Davidson JR, Jefferson JW, et al. Treatment of social phobia with gabapentin: a placebo-controlled study. J Clin Psychopharmacol 1999;19(4):341-8 (Pubitemid 29344848)
51. Pande AC, Feltner DE, Jefferson JW, et al. Efficacy of the novel anxiolytic pregabalin in social anxiety disorder: a placebo-controlled, multicenter study. J Clin Psychopharmacol 2004;24(2):141-9 (Pubitemid 38380837)
52. Barnett SD, Kramer ML, Casat CD, et al. Efficacy of olanzapine in social anxiety disorder: a pilot study. J Psychopharmacol 2002;16(4):365-8 (Pubitemid 35470582)
53. Vaishnavi S, Alamy S, Zhang W, et al. Quetiapine as monotherapy for social anxiety disorder: a placebo-controlled study. Prog Neuropsychopharmacol Biol Psychiatry 2007;31(7):1464-9 (Pubitemid 47302561)
54. Donahue CB, Kushner MG, Thuras PD, et al. Effect of quetiapine vs. placebo on response to two virtual public speaking exposures in individuals with social phobia. J Anxiety Disord 2009;23(3):362-8
55. Scahill L, Leckman JF, Schultz RT, et al. A placebo-controlled trial of risperidone in Tourette syndrome. Neurology 2003;60(7):1130-5 (Pubitemid 36418773)
56. Clark DB, Agras WS. The assessment and treatment of performance anxiety in musicians. Am J Psychiatry 1991;148(5):598-605
57. van Vliet IM, den Boer JA, Westenberg HG, Pian KL. Clinical effects of buspirone in social phobia: a double-blind placebo-controlled study. J Clin Psychiatry 1997;58(4):164-8 (Pubitemid 27199782)
58. Ravindran LN, Kim DS, Letamendi AM, Stein MB. A randomized controlled trial of atomoxetine in generalized social anxiety disorder. J Clin Psychopharmacol 2009;29(6):561-4
59. Tauscher J, Kielbasa W, Iyengar S, et al. Development of the 2nd generation neurokinin-1 receptor antagonist LY686017 for social anxiety disorder. Eur Neuropsychopharmacol 2010;20(2):80-7
60. Stein MB, Ravindran LN, Simon NM, et al. Levetiracetam in generalized social anxiety disorder: a double-blind, randomized controlled trial. J Clin Psychiatry 2010;71(5):627-31
61. Van Ameringen M, Mancini C, Pipe B, et al. An open trial of topiramate in the treatment of generalized social phobia. J Clin Psychiatry 2004;65(12):1674-8
62. Dunlop BW, Papp L, Garlow SJ, et al. Tiagabine for social anxiety disorder. Hum Psychopharmacol 2007;22(4):241-4 (Pubitemid 46939281)
63. Kinrys G, Pollack MH, Simon NM, et al. Valproic acid for the treatment of social anxiety disorder. Int Clin Psychopharmacol 2003;18(3):169-72 (Pubitemid 36571062)
64. Schneier FR, Blanco C, Campeas R, et al. Citalopram treatment of social anxiety disorder with comorbid major depression. Depress Anxiety 2003;17(4):191-6 (Pubitemid 36828744)
65. Connor KM, Cook JL, Davidson JR. Botulinum toxin treatment of social anxiety disorder with hyperhidrosis: a placebo-controlled double-blind trial. J Clin Psychiatry 2006;67(1):30-6 (Pubitemid 43213279)
66. Book SW, Thomas SE, Randall PK, Randall CL. Paroxetine reduces social anxiety in individuals with a co-occurring alcohol use disorder. J Anxiety Disord 2008;22(2):310-18
67. Adler LA, Liebowitz M, Kronenberger W, et al. Atomoxetine treatment in adults with attention-deficit/hyperactivity disorder and comorbid social anxiety disorder. Depress Anxiety 2009;26(3):212-21
68. Birmaher B, Axelson DA, Monk K, et al. Fluoxetine for the treatment of childhood anxiety disorders. J Am Acad Child Adolesc Psychiatry 2003;42(4):415-23 (Pubitemid 39625076)
69. Walkup JT, Albano AM, Piacentini J, et al. Cognitive behavioral therapy, sertraline, or a combination in childhood anxiety. N Engl J Med 2008;359(26):2753-66
70. Heimberg RG, Liebowitz MR, Hope DA, et al. Cognitive behavioral group therapy vs phenelzine therapy for social phobia: 12-week outcome. Arch Gen Psychiatry 1998;55(12):1133-41 (Pubitemid 28558287)
71. Liebowitz MR, Heimberg RG, Schneier FR, et al. Cognitive-behavioral group therapy versus phenelzine in social phobia: long-term outcome. Depress Anxiety 1999;10(3):89-98
72. Blanco C, Heimberg RG, Schneier FR, et al. A placebo-controlled trial of phenelzine, cognitive behavioral group therapy, and their combination for social anxiety disorder. Arch Gen Psychiatry 2010;67(3):286-95
73. Davidson JR, Foa EB, Huppert JD, et al. Fluoxetine, comprehensive cognitive behavioral therapy, and placebo in generalized social phobia. Arch Gen Psychiatry 2004;61(10):1005-13 (Pubitemid 39336534)
74. Blomhoff S, Haug TT, Hellstrom K, et al. Randomised controlled general practice trial of sertraline, exposure therapy and combined treatment in generalised social phobia. Br J Psychiatry 2001;179:23-30
75. Haug TT, Blomhoff S, Hellstrom K, et al. Exposure therapy and sertraline in social phobia: I-year follow-up of a randomised controlled trial. Br J Psychiatry 2003;182:312-18 (Pubitemid 36408282)
76. Knijnik DZ, Blanco C, Salum GA, et al. A pilot study of clonazepam versus psychodynamic group therapy plus clonazepam in the treatment of generalized social anxiety disorder. Eur Psychiatry 2008;23(8):567-74
77. Hofmann SG, Meuret AE, Smits JA, et al. Augmentation of exposure therapy with D-cycloserine for social anxiety disorder. Arch Gen Psychiatry 2006;63(3):298-304 (Pubitemid 43345354)
78. Guastella AJ, Richardson R, Lovibond PF, et al. A randomized controlled trial of D-cycloserine enhancement of exposure therapy for social anxiety disorder. Biol Psychiatry 2008;63(6):544-9
79. Guastella AJ, Howard AL, Dadds MR, et al. A randomized controlled trial of intranasal oxytocin as an adjunct to exposure therapy for social anxiety disorder. Psychoneuroendocrinology 2009;34(6):917-23
80. Lane C. Shyness; how normal behavior became a sickness. Yale University Press, New Haven, CT; 2007